LOGIN  |  REGISTER
Chimerix

Cognetivity Neurosciences (CSE: CGN) Stock Quote

Last Trade: C$0.02
Volume: 0
5-Day Change: -25.00%
YTD Change: 0%
Market Cap: C$1.340M

Latest News From Cognetivity Neurosciences

Latest Peer-Reviewed Study Published in Frontiers in Public Health Highlights Cost-Efficiency and Improved Clinical Outcomes from Using Cognetivity's Proprietary CognICA(TM) Technology, Showing Savings of Over £40 Million Per Year Compared with Traditional Cognitive Assessment Tools in Primary and Secondary Care Vancouver, British Columbia--(Newsfile Corp. - October 24, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTC... Read More
Collaboration With Highly Rated Healthcare Provider Opens US Healthcare Market for Brain Health for AI Powered CognICA, Enabling Patient Access to Latest Alzheimer's Drugs Vancouver, British Columbia--(Newsfile Corp. - October 11, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTC Pink: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity") , a leading artificial intelligence (AI) healthcare technology company is delighted... Read More
Program Designed to Identify Age-Related Brain Health Issues at an Early Stage, Allowing Effective Provision of Coordinated Care Vancouver, British Columbia--(Newsfile Corp. - October 3, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTC Pink: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity") , a leading AI healthcare technology company, is delighted to announce a collaboration with the Mediclinic Group ("Mediclinic"),... Read More
New Approach to Measuring Impact of Counselling to Deliver Next Generation Care to Mental Health Sufferers in North America Vancouver, British Columbia--(Newsfile Corp. - September 21, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity") , a leading artificial intelligence (AI) healthcare technology company is delighted to announce a partnership with No Fear... Read More
CognICA Chosen as Winner of Best AI Product in Healthcare Award at CogX Festival Vancouver, British Columbia--(Newsfile Corp. - September 13, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity") , a leading artificial intelligence (AI) healthcare technology company is delighted to announce that it has won a major AI technology award, with the company's CognICA™ platform... Read More
CognICA Shortlisted for Most Innovative AI Product in Healthcare Award at CogX Festival Vancouver, British Columbia--(Newsfile Corp. - September 5, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity") , a leading artificial intelligence (AI) healthcare technology company is pleased to announce that it has been shortlisted for a major AI technology award, with the... Read More
Cognetivity's Landmark ADePT Study, Funded by the UK Innovation Agency and Published in Leading Neuroscience Journal Demonstrates Unprecedented Sensitivity in Detecting Cognitive Impairment in Early Stage Alzheimer's Disease, Essential for Treatment With New Drugs Vancouver, British Columbia--(Newsfile Corp. - August 30, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE.1UB) ("the Company" or... Read More
Approval opens up a new major market for CognICA, providing a solution to the urgent requirement for large-scale early detection and monitoring for the rollout of incoming Alzheimer's disease drugs Vancouver, British Columbia--(Newsfile Corp. - August 2, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity") , a technology company that has created a unique Artificial... Read More
Vital breakthrough for Alzheimer's patients worldwide with Eisai's Leqembi FDA approval; Cognetivity Neurosciences' AI CognICA technology poised to play pivotal role in early detection and monitoring globally Vancouver, British Columbia--(Newsfile Corp. - July 7, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity") , a technology company that has created a unique... Read More
Partnership will accelerate adoption of Cognetivity's AI platform in Japan and other Asia-Pacific territories Vancouver, British Columbia--(Newsfile Corp. - June 13, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity") , is thrilled to announce a strategic partnership with CLAIRVO TECHNOLOGIES, Inc. (hereinafter, "Clairvo"), a wholly owned subsidiary of Marubeni... Read More
US Medicare & Medicaid to require data collection as part of drug reimbursement Vancouver, British Columbia--(Newsfile Corp. - June 6, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE:1UB) ("the Company" or "Cognetivity") , a technology company that has created a unique Artificial Intelligence (AI) powered brain health screening and monitoring platform for use in medical, commercial and consumer... Read More
Agreement aims at further development of Cognetivity's AI (Artificial Intelligence) platform through investigating comorbidities in diabetes and dementia Vancouver, British Columbia--(Newsfile Corp. - May 31, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity"), a leading provider of brain health solutions powered by AI, is excited to announce a collaboration with the... Read More
The news highlights the urgent need for more consistent, wide scale detection of the disease at an early stage Vancouver, British Columbia--(Newsfile Corp. - May 9, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity") is pleased to note Eli Lilly & Co.'s results for its experimental drug for Alzheimer's disease, which demonstrated slowing the progress of the disease in... Read More
Company to provide its AI-powered cognitive assessment technology to policyholders in Japanese market to promote proactive approach to brain health Vancouver, British Columbia--(Newsfile Corp. - April 25, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity") has entered into an agreement with Mitsui Sumitomo Aioi Life Insurance ("MSA") to work together to provide... Read More
Appointment brings deep industry and investment experience to the company, helping the company's expansion and growth globally Vancouver, British Columbia--(Newsfile Corp. - April 20, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) (the "Company" or "Cognetivity") , a technology company that has created a unique brain health assessment platform for use in medical, commercial and consumer... Read More
Company presents key data on measuring impact of sleep disorders on brain health; University of Oxford extends collaboration on monitoring changes in cognition of older adults Vancouver, British Columbia--(Newsfile Corp. - March 23, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) (the "Company" or "Cognetivity") , a technology company that has created a unique brain health screening platform for... Read More
Agreement sees Cognetivity expand commercial offering into sports and fitness market, with cutting-edge assessment and monitoring technology made available to customers of brain health supplement subscription service Vancouver, British Columbia--(Newsfile Corp. - March 15, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) (the "Company" or "Cognetivity") , a technology company that has created a... Read More
Expansion of first-phase deployment follows excellent published results, showing cross-cultural validity, leading to further expansion and market traction in Asia Vancouver, British Columbia--(Newsfile Corp. - March 8, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) (the "Company" or "Cognetivity"), a technology company that has created a unique brain health screening platform for use in medical,... Read More
Latest Agreement Signals Continued, Rapid Commercial Growth in Middle East Region Vancouver, British Columbia--(Newsfile Corp. - February 23, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) (the "Company" or "Cognetivity") , a technology company that has created a unique brain health screening platform for use in medical, commercial and consumer environments, is pleased to announce that it has... Read More
Peer-reviewed article demonstrates effectiveness of company's technology in major disease area with global application for the detection and monitoring of disease Vancouver, British Columbia--(Newsfile Corp. - February 22, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (FSE: 1UB) (OTCQB: CGNSF) (the "Company" or "Cognetivity") today announced the publication of its latest peer-reviewed scientific paper on its Integrated... Read More
With global interest in AI at an all-time high, latest update to Cognetivity's flagship medical device affirms company's sustained commitment to being at the forefront of AI in healthcare Vancouver, British Columbia--(Newsfile Corp. - February 14, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) (the "Company" or "Cognetivity") , a technology company that has created a unique brain health screening... Read More
Demonstrable sensitivity and clinical usability of Cognetivity's screening and monitoring tool leaves the company well placed to support the dawning era of targeted therapies for neurodegenerative disease Vancouver, British Columbia--(Newsfile Corp. - January 24, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) (the "Company" or "Cognetivity") , a technology company that has created a unique brain... Read More
Key achievements in 2022 included continued collaboration with global pharmaceutical firms working in neurodegenerative disease, new and ongoing commercial deployments spanning three continents, and completion of a fundraising round worth CAD 4.5 million Vancouver, British Columbia--(Newsfile Corp. - January 10, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FWB: 1UB) (the "Company" or "Cognetivity") , a... Read More
Policy paper published by UK's leading dementia research charity emphasizes importance of early detection in dementia diagnosis, citing Cognetivity's CognICA(TM) as an innovative solution for use in primary care Vancouver, British Columbia--(Newsfile Corp. - December 13, 2022) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) (the "Company" or "Cognetivity") , a technology company that has created a... Read More
Cue Biopharma

COPYRIGHT ©2023 HEALTH STOCKS HUB